Compare AbCellera Biologics Inc (ABCL) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Clear Secure Inc — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Clear Secure Inc trades at $55.46 (market cap $5.63B). The key difference: Clear Secure Inc is far larger — about 2.4× AbCellera Biologics Inc's market cap, and Clear Secure Inc pays a 1.07% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | YOU | |
|---|---|---|
Market Cap | $2.35B | $5.63B |
Sector | Health | Technology |
52-Week High | $8.12 | $62.36 |
52-Week Low | $2.78 | $28.38 |
Enterprise Value | $1.99B | $4.94B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Clear Secure (YOU) trades at $56.74, up 5.48% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated at P/E 45.39. Recent Q1 2026 earnings beat expectations, and the AWS partnership expansion signals growth potential. Analyst sentiment is mixed with 44% buy ratings and consensus target near current price.
Outlook remains positive given strong member growth and cash flow generation, but high valuation multiples and competitive pressures present risks. The stock's technical overbought condition near resistance at $58 suggests potential near-term consolidation before further upside. Institutional interest appears balanced with moderate net cash flow growth supporting expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
